It is therefore a therapeutic option for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), and to maintain P2Y12 inhibition when oral therapy is interrupted for any reason [92,93]. The gene discussed is P2RY12; the disease is coronary artery disorder.